과민성장증후군과 연관된 중개연구 현황 = Current Status of Translational Research on Irritable Bowel Syndrome

다국어 초록 (Multilingual Abstract)

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. The pathophysiology of IBS is not completely understood. Genetic, immune, environmental, inflammatory, neurological and psychological factors contribute to the risk of this condition. Traditional research explored gastrointestinal motor abnormalities, central neural dysregulation, abnormal psychological features, and visceral hypersensitivity. More recent investigations consider bacterial overgrowth, abnormal serotonin pathways, altered gut flora, immune activation and mucosal inflammation. The purpose of this article is to review recent translational research concerning the pathophysiology, biomarker and genetic factors of IBS and to encourage IBS research in Korea. (Korean J Gastroenterol 2016;68:138-142)

참고문헌 (Reference)

1 Ford AC, "Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care" 145 : 1262-1270, 2013

2 Nasser Y, "Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome" 26 : 455-469, 2014

3 Lembo AJ, "Use of serum biomarkers in a diagnostic test for irritable bowel syndrome" 29 : 834-842, 2009

4 Drossman DA, "U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact" 38 : 1569-1580, 1993

5 Giovanni Barbara, "The Immune System in Irritable Bowel Syndrome" 대한소화기 기능성질환∙운동학회 17 (17): 349-359, 2011

6 Dong Won Park, "The Differences in Prevalence and Sociodemographic Characteristics of Irritable Bowel Syndrome According to Rome II and Rome III" 대한소화기 기능성질환∙운동학회 16 (16): 186-193, 2010

7 Sood R, "Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers" 42 : 491-503, 2015

8 Windmueller HG, "Source and fate of circulatingcitrulline" 241 : E473-E480, 1981

9 Mujagic Z, "Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders" 40 : 288-297, 2014

10 Pata C, "Serotonin transporter gene polymorphism in irritable bowel syndrome" 97 : 1780-1784, 2002

11 Valdez-Morales EE, "Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2" 108 : 1634-1643, 2013

12 van der Veek PP, "Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome" 100 : 2510-2516, 2005

13 Cenac N, "Role for protease activity in visceral pain in irritable bowel syndrome" 117 : 636-647, 2007

14 Cenac N, "Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome" 149 : 433-444, 2015

15 Lee SY, "Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study" 79 : 196-201, 2009

16 Michael Camilleri, "Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea" American Physiological Society 311 (311): G365-G376, 2016

17 Camilleri M, "Peripheral mechanisms in irritable bowel syndrome" 367 : 1626-1635, 2012

18 Buhner S, "Neuronal activation by mucosal biopsy supernatants from irritable bowel syndrome patients is linked to visceral sensitivity" 99 : 1299-1311, 2014

19 Dothel G, "Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome" 148 : 1002-1011, 2015

20 Lutgens LC, "Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests" 103 : 191-199, 2005

21 Van Kerkhoven LA, "Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome" 26 : 979-986, 2007

22 Barbara G, "Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome" 132 : 26-37, 2007

23 Annaházi A, "Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS" 108 : 1322-1331, 2013

24 Beyder A, "Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome" 146 : 1659-1668, 2014

25 Gazouli M, "Lessons learned--resolving the enigma of genetic factors in IBS" 13 : 77-87, 2016

26 O'Mahony L, "Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles" 128 : 541-551, 2005

27 Andresen V, "Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders?" 130 : 1985-1994, 2006

28 Bengtson MB, "Irritable bowel syndrome in twins: genes and environment" 55 : 1754-1759, 2006

29 Enck P, "Irritable bowel syndrome" 2 : 16014-, 2016

30 Bischoff SC, "Intestinal permeability--a new target for disease prevention and therapy" 14 : 189-, 2014

31 Ford AC, "IBS in 2010: advances in pathophysiology, diagnosis and treatment" 8 : 76-78, 2011

32 El-Serag HB, "Health-related quality of life among persons with irritable bowel syndrome: a systematic review" 16 : 1171-1185, 2002

33 Lu CL, "Gender difference on the symptoms, health-seeking behaviour, social impact and sleep quality in irritable bowel syndrome: a Rome II-based survey in an apparent healthy adult Chinese population in Taiwan" 21 : 1497-1505, 2005

34 Douglas A. Drossman, "Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV" Elsevier BV 150 (150): 1262-1279.e2, 2016

35 Annaházi A, "Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice" 144 : 209-217, 2009

36 Saito YA, "Familial aggregation of irritable bowel syndrome: a family case-control study" 105 : 833-841, 2010

37 Langhorst J, "Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome" 104 : 404-410, 2009

38 Martínez C, "Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier" 62 : 1160-1168, 2013

39 Dolwani S, "Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology" 20 : 615-621, 2004

40 Sood R, "Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?" 11 : 683-691, 2014

41 Rey E, "Determinants of quality of life in irritable bowel syndrome" 42 : 1003-1009, 2008

42 Bashashati M, "Cytokine imbalance in irritable bowel syndrome: a systematic review and metaanalysis" 26 : 1036-1048, 2014

43 Fritscher-Ravens A, "Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome" 147 : 1012-1020, 2014

44 Sood R, "Combining biomarkers in irritable bowel syndrome:a forward step toward making a positive diagnosis and directing therapy?" 148 : 1471-1473, 2015

45 van Vliet MJ, "Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients" 53 : 1188-1194, 2009

46 Crenn P, "Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction" 27 : 328-339, 2008

47 Facer P, "Chromogranin: a newly recognized marker for endocrine cells of the human gastrointestinal tract" 89 : 1366-1373, 1985

48 Vora P, "Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells" 173 : 5398-5405, 2004

49 Kim HJ, "Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders" 53 : 829-837, 2004

50 Lesch KP, "Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region" 274 : 1527-1531, 1996

51 Tana C, "Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome" 22 : 512-519, 2010

52 Ohman L, "Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?" 107 : 440-447, 2012

53 Barbara G, "Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome" 126 : 693-702, 2004

54 Saito YA, "A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome" 19 : 465-470, 2007

55 Jones MP, "A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads" 39 : 426-437, 2014